GSA Capital Partners LLP Buys Shares of 555,944 MaxCyte, Inc. $MXCT

GSA Capital Partners LLP purchased a new stake in MaxCyte, Inc. (NASDAQ:MXCT) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 555,944 shares of the company’s stock, valued at approximately $684,000. GSA Capital Partners LLP owned about 0.52% of MaxCyte as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Marquette Asset Management LLC bought a new stake in shares of MaxCyte during the 2nd quarter worth $351,000. Bank of America Corp DE boosted its stake in MaxCyte by 30.1% in the first quarter. Bank of America Corp DE now owns 127,258 shares of the company’s stock valued at $89,000 after buying an additional 29,457 shares in the last quarter. Renaissance Technologies LLC grew its position in MaxCyte by 153.3% in the first quarter. Renaissance Technologies LLC now owns 1,993,200 shares of the company’s stock valued at $1,400,000 after acquiring an additional 1,206,300 shares during the last quarter. Brooklands Fund Management Ltd acquired a new position in MaxCyte during the first quarter worth about $1,538,000. Finally, Bank of New York Mellon Corp raised its stake in MaxCyte by 18.3% during the first quarter. Bank of New York Mellon Corp now owns 403,937 shares of the company’s stock worth $284,000 after acquiring an additional 62,477 shares in the last quarter. Institutional investors and hedge funds own 68.81% of the company’s stock.

Analyst Ratings Changes

MXCT has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of MaxCyte from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings cut shares of MaxCyte from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, MaxCyte has a consensus rating of “Hold” and a consensus target price of $5.00.

MaxCyte Stock Up 9.4%

NASDAQ MXCT opened at $1.39 on Thursday. The company has a market cap of $143.46 million, a price-to-earnings ratio of -4.21 and a beta of 1.48. MaxCyte, Inc. has a twelve month low of $0.64 and a twelve month high of $1.86. The business’s fifty day moving average is $1.21 and its 200 day moving average is $0.99.

MaxCyte (NASDAQ:MXCT) last issued its earnings results on Wednesday, August 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The business had revenue of $6.50 million during the quarter, compared to analysts’ expectations of $6.51 million. MaxCyte had a negative return on equity of 18.92% and a negative net margin of 114.77%. On average, research analysts anticipate that MaxCyte, Inc. will post -0.25 earnings per share for the current fiscal year.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.